Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1835 results
November 2016
-
In The News
The price of drugs should reflect the value they deliver
In Forbes commentary, Novartis CEO says industry should focus on outcomes for patients and healthcare systems. -
Featured News
When innovation draws a new future for patient treatments
A recent summit explored how technological advances could impact patient care.
-
Featured News
Novartis, Medikidz® and the COPD Foundation: a partnership of superhero proportions
We teamed up with Medikidz and the COPD Foundation to develop a creative way to explain COPD to children.
-
Press Release
Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer
Priority Review based on Phase III MONALEESA-2 trial, which showed LEE011 plus letrozole, as initial treatment for advanced breast cancer, significantly extended progression-free survival compared…
October 2016
-
Story Discovery
Experimental treatment clears malaria infections in small clinical study
Compound offers a potential tool for fighting drug-resistant malaria parasites.
-
Press Release
Novartis Wins Two Prestigious Prix Galien Foundation Awards; Gleevec® recognized as "Discovery of the Decade" for Best Pharmaceutical Product, Cosentyx® as Best Biotechnology Product
Basel, October 31, 2016 - Novartis has been awarded the prestigious 2016 Prix Galien USA Award for Best Biotechnology Product for Cosentyx® (secukinumab), as well as the Prix Galien Foundation "… -
Featured News
Novartis dialogue to explore solutions to the rise of chronic diseases in the developing world
The event, called “Improving care for chronic patients in lower-income countries: the patient journey,” will take place November 29, 2016, on the Novartis Campus in Basel, Switzerland and will also be webcast.
-
Press Release
Novartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbusters
Q3 net sales (-1% cc[2] and USD) broadly in line with prior year due to strong performance of Growth Products Gilenya (USD 790 million, +15% cc) continued double-digit growth Cosentyx (USD 301… -
Press Release
Novartis erzielt im dritten Quartal solide Ergebnisse, wobei die Wachstumsprodukte[1] den Verlust des Patents für Gleevec wettmachen; mehrere positive Daten für potenzielle Blockbuster
Dank starker Performance der Wachstumsprodukte bleibt der Nettoumsatz im dritten Quartal (-1% kWk[2] und USD) weitgehend unverändert gegenüber dem Vorjahreszeitraum Gilenya (USD 790 Millionen, +… -
Press Release
Novartis a réalisé un troisième trimestre solide, les produits de croissance[1] ayant compensé l'expiration du brevet de Glivec; plusieurs résultats positifs concernant des blockbusters potentiels
Chiffre d'affaires net du T3 (-1% tcc[2] et USD) largement comparable au T3 2015 grâce à l'excellente performance des produits de croissance Gilenya (USD 790 millions, +15% tcc) a poursuivi sa… -
Press Release
Alcon launches the CyPass® Micro-Stent at the American Academy of Ophthalmology (AAO) 2016 annual meeting
Alcon to host first live training program on the use of the CyPass® Micro-Stent, a minimally invasive glaucoma surgical device to treat cataract patients with mild to moderate primary open-angle… -
Story Discovery
The Evolution of a Scientist
A middle school student curious about science grows into a college-bound scientist.